Paper17655729
FLT3 inhibition in acute myeloid leukaemia.
Knapper S. Br J Haematol, 2007. Cited by 56 papers, by iCite.
Cite this record
ConductScience Library. FLT3 inhibition in acute myeloid leukaemia. Papers, record 17655729. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17655729
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Leukemia, Myeloid | Major topic |
| fms-Like Tyrosine Kinase 3 | Major topic |
| Acute Disease | |
| HSP90 Heat-Shock Proteins | |
| Humans | |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | |
| Remission Induction |
Source PubMed
Cited by27
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 56 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39367387 | AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies. | Exp Hematol Oncol | 2024 | https://conductscience.org/library/papers/39367387 | PubMed |
| 34172833 | Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia. | Commun Biol | 2021 | https://conductscience.org/library/papers/34172833 | PubMed |
| 33832508 | Combating drug resistance in acute myeloid leukaemia by drug rotations: the effects of quizartinib and pexidartinib. | Cancer Cell Int | 2021 | https://conductscience.org/library/papers/33832508 | PubMed |
| 28895560 | Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia. | Leukemia | 2018 | https://conductscience.org/library/papers/28895560 | PubMed |
| 26438511 | Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. | Blood | 2015 | https://conductscience.org/library/papers/26438511 | PubMed |
| 26172401 | Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia. | Leukemia | 2015 | https://conductscience.org/library/papers/26172401 | PubMed |
| 25510283 | Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies? | Immunol Rev | 2015 | https://conductscience.org/library/papers/25510283 | PubMed |
| 24749672 | Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia. | Expert Opin Investig Drugs | 2014 | https://conductscience.org/library/papers/24749672 | PubMed |
| 24468836 | Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia? | Curr Opin Hematol | 2014 | https://conductscience.org/library/papers/24468836 | PubMed |
| 24280675 | Heat shock protein 90 and role of its chemical inhibitors in treatment of hematologic malignancies. | Pharmaceuticals (Basel) | 2012 | https://conductscience.org/library/papers/24280675 | PubMed |
| 23321254 | Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target. | Blood | 2013 | https://conductscience.org/library/papers/23321254 | PubMed |
| 22927251 | Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia. | Blood | 2012 | https://conductscience.org/library/papers/22927251 | PubMed |
| 22797419 | FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia. | Leukemia | 2013 | https://conductscience.org/library/papers/22797419 | PubMed |
| 22754594 | Heat shock protein 90 inhibition: rationale and clinical potential. | Ther Adv Med Oncol | 2012 | https://conductscience.org/library/papers/22754594 | PubMed |
| 21788404 | Online nanoflow multidimensional fractionation for high efficiency phosphopeptide analysis. | Mol Cell Proteomics | 2011 | https://conductscience.org/library/papers/21788404 | PubMed |
| 21453545 | Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications. | J Hematol Oncol | 2011 | https://conductscience.org/library/papers/21453545 | PubMed |
| 21080208 | Evaluation of a multi-kinase inhibitor KRC-108 as an anti-tumor agent in vitro and in vivo. | Invest New Drugs | 2012 | https://conductscience.org/library/papers/21080208 | PubMed |
| 20514303 | High transcript level of FLT3 associated with high risk of relapse in pediatric acute myeloid leukemia. | J Korean Med Sci | 2010 | https://conductscience.org/library/papers/20514303 | PubMed |
| 20019052 | A robust error model for iTRAQ quantification reveals divergent signaling between oncogenic FLT3 mutants in acute myeloid leukemia. | Mol Cell Proteomics | 2010 | https://conductscience.org/library/papers/20019052 | PubMed |
| 20007803 | FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. | Blood | 2010 | https://conductscience.org/library/papers/20007803 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| FLT3 | 2322 | PubTator's text mining | https://conductscience.org/library/genes/2322 | NCBI Gene |
| KMT2A | 4297 | PubTator's text mining | https://conductscience.org/library/genes/4297 | NCBI Gene |
| RET | 5979 | PubTator's text mining | https://conductscience.org/library/genes/5979 | NCBI Gene |
| TXK | 7294 | PubTator's text mining | https://conductscience.org/library/genes/7294 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17655729
GET https://conductscience.org/api/papers/v1/17655729/cited_by?page=2